Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Humacyte ( (HUMA) ) has issued an update.
Humacyte announced that the FDA has granted full approval for SYMVESS, an acellular tissue-engineered vessel, for use in adults with extremity arterial injuries where autologous vein grafts are not feasible. This approval marks a significant advancement in regenerative medicine, offering a new treatment option that promises to improve trauma care by reducing amputation rates and infection risks. The company is poised for a commercial launch, having prepared an experienced sales team, and anticipates SYMVESS will become the preferred choice for complex vascular injuries, both civilian and military.
More about Humacyte
Humacyte, Inc. is a biotechnology platform company focused on developing universally implantable, bioengineered human tissues at commercial scale. Their primary product, SYMVESS, is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for arterial replacement and repair.
YTD Price Performance: 21.83%
Average Trading Volume: 3,114,708
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $445.2M
Learn more about HUMA stock on TipRanks’ Stock Analysis page.
